Loading stock data…
BTAI
$1.20-0.03 (-2.44%)
Market ClosedLast close May 1
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioXcel Therapeutics, Inc. in the Healthcare sector is trading at $1.20. The stock is currently near its 52-week low of $1.01, remaining 45.2% below its 200-day moving average. Technical signals show neutral RSI of 64 and bullish MACD crossover, explaining why BTAI maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 64) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.20
Potential Upside
5%
Whystock Fair Value$1.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$14.00+1066.7%
Range$1.00 – $38.00
Fundamentals
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United Stat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
73.22%
Volume
Today's trading volume
1.20M
Recent News
H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns
We recently compiled a list of the 10 Best Beaten Down Stocks to Invest in According to Analysts. BioXcel Therapeutics, Inc. is one of the best 52-week low stocks. TheFly reported on April 2 that H.C. Wainwright lowered its price target on BTAI to $5 from $6 while maintaining a Buy rating. The firm attributed […]
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks
BioXcel Therapeutics is back in focus after a slight trim to one fair value estimate to US$14.00 from US$14.25, while another piece of Street research sets a separate price target at US$17 and a more cautious voice cuts its target to US$6 from US$10. These moves reflect the ongoing split between analysts who highlight the long term potential of BXCL501 and those who are more concerned about equity dilution and funding pressure. Read on to see how to track this evolving narrative and what it...
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks
The key shift in the BioXcel Therapeutics story right now sits in the range of Street price targets, with one cut from US$10 to US$6 while other targets extend into the mid to high single digits and above, including US$10 and US$17. This spread reflects a clear divide between analysts who focus on the potential of the at home agitation and broader neuropsychiatry portfolio and those who put more weight on ongoing and expected equity dilution. As you read on, you will see how these moving...
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs
The latest research update on BioXcel Therapeutics cuts the price target from US$10 to US$6, alongside a modest trim in the fair value estimate from $15.25 to $14.25. Bulls see this move as a recalibration that still leaves room for upside, while bears point to the lower target as a signal that equity dilution and funding needs are front and center. As you read on, you will see how these shifting views shape the evolving narrative around the stock and what to watch next. Stay updated as the...
1 Top Penny Stock to Watch Now
This small-cap biotech is chasing a big breakthrough in 2026.